• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Cost-effectiveness of a photopethysmographic procedure for screening for atrial fibrillation in 6 European countries
ConclusionThe model results showed a strong dependence of the results on the country-specific costs for stroke treatment. The use of the investigated screening method is close to cost-neutral or cost-reducing in the Western European countries and Greece. In countries with low price levels, higher cost increases due to AF screening are to be expected. Lower costs of anticoagulation, which are expected due to the upcoming patent expiry of direct anticoagulants, have a positive effect on the cost result.
Source: Health Economics Review - February 26, 2022 Category: International Medicine & Public Health Source Type: research

Rivaroxaban for non-valvular atrial fibrillation and venous thromboembolism in the Netherlands: a real-world data based cost-effectiveness analysis.
CONCLUSIONS: In patients with NVAF or VTE, rivaroxaban treatment is likely to be cost-effective and potentially cost-saving alternative to VKA in the Netherlands. PMID: 30614320 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - January 8, 2019 Category: Health Management Tags: J Med Econ Source Type: research

Predictors for total hospital and cardiology cost claims among patients with atrial fibrillation initiating dabigatran or acenocoumarol in the Netherlands.
CONCLUSION: Dabigatran treatment was as a predictor for lower cardiology costs and lower total hospital care costs in AF patients that initiated oral anticoagulation. PMID: 28766370 [PubMed - as supplied by publisher]
Source: Journal of Medical Economics - August 4, 2017 Category: Health Management Tags: J Med Econ Source Type: research

The burden of stroke in the Netherlands: estimating quality of life and costs for 1 year poststroke
Conclusions We found lower patient costs and higher QoL than expected. This may be explained by the good state of health of our study population and by change in the Dutch healthcare system, which has led to considerable shorter hospitalisation poststroke. Future research must question the use of the EQ-5D-3L in a similar population due to ceiling effects. Trial registration number NTR3051.
Source: BMJ Open - November 27, 2015 Category: Journals (General) Authors: van Eeden, M., van Heugten, C., van Mastrigt, G. A. P. G., van Mierlo, M., Visser-Meily, J. M. A., Evers, S. M. A. A. Tags: Open access, Health economics Research Source Type: research